This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Heink, S. Articles by Krüger, E. Search for Related Content PubMed PubMed Citation Articles by Heink, S. Articles by Krüger, E.

Tumor Cell Lines Expressing the Proteasome Subunit Isoform LMP7E1 Exhibit Immunoproteasome Deficiency

Institute of Biochemistry, Charité-Universitätsmedizin Berlin, Berlin, Germany

Requests for reprints: Elke Krüger, Institut für Biochemie, Charité-Universitätsmedizin Berlin, CCM, Monbijoustrasse 2, 10117 Berlin, Germany. Phone: 49-30-450-528186; Fax: 49-30-450-528921; E-mail: elke.krueger{at}charite.de.

The immune system can recognize antigenic peptides derived from tumors by their presentation on MHC class I complexes to CTLs. Immunoproteasomes (i20S) can substantially enhance the MHC class I peptide repertoire, making down-regulation of i20S an important strategy of tumor cells in manipulating immune surveillance. Here, we report that human cancer cells express the nonfunctional immunosubunit-variant LMP7E1, in addition to, or instead of LMP7E2, in response to IFN-. This preferential expression of LMP7E1 and the consequent down-regulation of LMP7E2 results in i20S deficiency. The molecular explanation for this phenomenon is the incapacity of LMP7E1 to interact efficiently with the proteasome maturation protein, which regularly recruits LMP7E2 into nascent i20S precursor complexes. In contrast to previous reports, i20S formation in these cancer cells cannot be restored by IFN- treatment. However, expression of LMP7E2 in these cells restores the i20S-deficient phenotype. Thus, our data describe a novel mechanism that contributes to the process of oncogenesis. (Cancer Res 2006; 66(2):649-52)

This article has been cited by other articles:

				J. Dannull, D.-T. Lesher, R. Holzknecht, W. Qi, G. Hanna, H. Seigler, D. S. Tyler, and S. K. Pruitt Immunoproteasome down-modulation enhances the ability of dendritic cells to stimulate antitumor immunity Blood, December 15, 2007; 110(13): 4341 - 4350. [Abstract] [Full Text] [PDF]